Quanterix, a company digitizing biomarker analysis to accurately measure change for precision health, has announced it is making a strategic investment in ImmunArray, a molecular diagnostics company advancing the development of novel, multi-marker tests for complex diseases with compelling levels of accuracy. As part of the deal, ImmunArray gains access to Quanterix Simoa technology. Both companies are pioneering new approaches to medical diagnoses in complementary areas of neurological disease, focusing on the identification and analysis of molecular biomarkers in the blood.
According to the HHS, nearly one-third of all injury-related deaths in the U.S. involve a traumatic brain injury (TBI). Further, about 75% of TBIs that occur each year are concussions or other forms of mild TBI, which are far more difficult to diagnose. With this agreement, Quanterix and ImmunArray will work together to continue advancing research and technology in order to provide an accurate method for detecting mild to moderate traumatic brain injury in the future. Also, Quanterix will add select ImmunArray markers to its multiplexing panel for the neurology research market. These additions provide researchers with the ability to measure multiple proteins simultaneously at the single molecule level using Quanterix’ Simoa technology.
“This investment and collaboration agreement enhance our two companies’ collective ability to provide the broadest portfolio of biomarker panels to the research market utilizing highly sensitive technology,” said Donna Edmonds, chairman and CEO of ImmunArray. “As we continue to advance the research and development of panels for the detection and diagnosis of traumatic brain injury and other neurodegenerative diseases in acute and chronic settings, we will now have added support from Quanterix to help accelerate the development of important diagnostic tools. We welcome this vote of confidence from our colleagues at Quanterix and look forward to working closely with them.”
“We are excited to expand our collaboration with ImmunArray,” said Kevin Hrusovsky, CEO and executive chairman, Quanterix. “ImmunArray has built an attractive portfolio of brain health biomarkers that nicely complement our existing menu of assays. We are also delighted that they will utilize our Simoa technology to further develop their portfolio for clinical utility.
ImmunArray and Quanterix are both privately held, funded largely through venture capital investments and have been grant recipients of the GE-NFL Head Health Challenge to continue their work in improving diagnosis and treatment for mild to moderate traumatic brain injury.
